Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 231-104-6 | CAS number: 7439-95-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Remarks:
- combined repeated dose and reproduction / developmental screening
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Well documented study.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 011
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- GLP compliance:
- not specified
- Limit test:
- no
Test material
- Reference substance name:
- Magnesium chloride
- EC Number:
- 232-094-6
- EC Name:
- Magnesium chloride
- Cas Number:
- 7786-30-3
- IUPAC Name:
- magnesium dichloride
- Test material form:
- solid: compact
- Details on test material:
- Magnesium chloride hexahydrate, MgCl2 6H20,
water content (specification): 51-55% (53.4%)
Colour: colourless
Physical state: solid, crystals
Storage: at room temperature, in a tightly closed package
Solvent: water
Stability after opening: instable after repeated contact to air
pH: 5.5 - 7.0 (5% solution at 20° C)
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
Young healthy male and nulliparous, non pregnant, female rats [strain: Wistar Crl:WI] (Full-Barrier), were used in this study. The animals were derived from a controlled full barrier maintained breeding system (SPF) (Source: Charles River, 97633 Sulzfeld, Germany).
At the beginning of the study, the age of the animals was 8-9 weeks. The range of the body weight was:
Females: 144.32 to 216.48 g, (mean: 180.40 g, ± 20%= 36.08 g)
Males: 211.18 to 316.77 g, (mean: 263.98 g, ± 20%= 52.80 g).
ENVIRONMENTAL CONDITIONS
After an adequate acclimatisation period (at least five days), the animals were barrier maintained (full-barrier) in air conditioned rooms under the following conditions: temperature: 22 ± 3 °C, relative humidity: 55 ± 10%, artificial light, sequence being 12 hours light, 12 hours dark, air change: 10 x / hour, free access to Altromin 1324 maintenance diet, free access to tap water, sulphur acidified to a pH of approximately 2.8 (drinking water, municipal residue control, microbiol. controlled periodically), housed individually in IVC cages, type III H, polysulphone cages on Altromin saw fibre bedding
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on oral exposure:
- MgCl2, 6H2O was formulated in deionised water with administration volume of 10 mL/kg body weight. Control animals were handled identically as the treated groups and received deionised water in a similar volume as the treated groups.
MgCl2, 6H2O formulation was prepared freshly and administered daily during 14 days pre mating and 14 days mating period in both male and female animals, and during gestation period and up to post natal day 3 in females. Males were dosed for 28-29 days. Dose volumes were adjusted weekly based on body weight measurement. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- There were 3 sorts of sample:
1/ Samples for the nominal concentration verification were taken in study week 1 (first week of pre mating period), 3 (first week of mating), 5 (gestation) and 7 (gestation/lactation).
2/ Samples for homogeneity were taken from the top, middle and bottom of the high dose and low dose preparation in study week 1 and 5.
3/ Samples for stability analysis were taken in the first week of the study. After preparation small portions (in triplicate) were frozen immediately at -20 °C (0 h) and small portions were kept for 6 hours at room temperature before they were frozen at -20 °C (6h) to determine the stability of the test item in the vehicle.
All formulation samples were stored frozen (approximately -20°C) till the shipment to analytic laboratory and analysis were performed.
In conclusion, the dose formulation analysis of samples collected during study week 1, 3, 5 and 7 from LD, MD and HD group showed very good recovery. - Duration of treatment / exposure:
- 28-29 days for males
maximum 54 days for females (14 days pre mating, 14 days mating, during gestation period and up to post natal day 3) - Frequency of treatment:
- 7 days per week
Doses / concentrationsopen allclose all
- Remarks:
- Doses / Concentrations:
250 mg/kg bw/day
Basis:
actual ingested
- Remarks:
- Doses / Concentrations:
500 mg/kg bw/day
Basis:
actual ingested
- Remarks:
- Doses / Concentrations:
1000 mg/kg bw/day
Basis:
actual ingested
- No. of animals per sex per dose:
- 98 animals were included in the study. Control- 12/12 (Male/Female), LD- 10/10 (Male/Female), MD- 12/12 (Male/Female) and HD- 15/15 (Male/Female)
- Control animals:
- yes, plain diet
- Details on study design:
- The animals were randomly assigned (using Microsoft Excel template) to the dose/control groups, each animal was assigned a unique identification number and caged individually.
The test item was administered by gavage using a gavaging cannula. The maximum dose volume administered was 10 mL / kg body weight.
For each animal the individual dosing volume was calculated on the basis of the most recently measured body weight. - Positive control:
- no
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- General clinical observations were made twice a day except during weekend and holidays where observations were made only once, approximately at the same time each day and considering the peak period of anticipated effects after dosing
- Cage side observations checked in table were included.
DETAILED CLINICAL OBSERVATIONS: Yes
- Once before the first exposure, and once a week thereafter.
- Clinical observations included spontaneous activity, lethargy, recumbent position, convulsions, tremors, apnea, asphyxia, vocalization, diarrhea, changes in the skin and fur, eyes and mucous membranes (salivation, discharge), and piloerection and pupil size. Changes in gait, posture, response to handling as well as the presence of clonic or tonic movements, stereotypes, difficult or prolonged parturition or bizarre behaviour were recorded.
BODY WEIGHT: Yes
- Time schedule for examinations: males weekly during the entire study period and at terminal sacrifice. Females were weighed weekly during pre mating period, on gestation day 0, 7, 14, 20 and on PND 1 (within 24 hours of parturition) and 4 along with pups.
FOOD CONSUMPTION: Yes
- Food consumption was measured on corresponding day of body weight (in males only during pre mating period) after beginning of the dose administration. Food consumption was not measured during mating period.
WATER CONSUMPTION No
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood: Day 28 of treatment
- Anaesthetic used for blood collection: Yes: Isoflourane anesthesia
- Animals fasted: Yes
- How many animals: five males and five females randomly selected from each group.
- Parameters checked in table were examined: haematocrit, haemoglobin, erythrocyte count, total and differential leucocyte count, platelet count, blood clotting time.
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: Day 28 of treatment
- Animals fasted: Yes
- How many animals: five males and five females of each group
- Parameters checked in table were examined: cholesterol, urea, creatinine, total protein and albumin, two enzymes indicative of hepatocellular effects (such as alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase).
URINALYSIS: Yes
- Time schedule for collection of urine: day 28 of treatment
- Metabolism cages used for collection of urine: No data
- Animals fasted: Yes
- How many animals: seven randomly selected males of HD group, six randomly selected males of control and MD group and five randomly selected males of LD group at the terminal sacrifice.
- Parameters checked in table were examined.
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: during the last week of treatment in males and on day 3 of the lactation in females (only lactating females were evaluated).
- Dose groups that were examined: five randomly selected males and females from each group
- Battery of functions tested: Sensory reactivity to different modalities, grip strength and motor activity assessments and other behaviour observations - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
- Males were sacrificed after the completion of mating period (total dosing of 28-29 days) and females were sacrificed on respective post natal day 4 along with pups by using high dose of sodium pentobarbital. However, in the animals randomly selected for the blood collection, anaesthesia solution (Ketamin/Xylazin, 2:1) was used. At the time of sacrifice or death during the study, the adult animals were subjected to a full, detailed gross necropsy which includeed careful examination of the external surface of the body, all orifices and the cranial, thoracic and abdominal cavities and their contents. Special attention was paid to the organs of the reproductive system.
ORGAN WEIGHT: Yes
- Reproductive organs from all animals were weighed (testes, epididymides, prostate, seminal vesicle with coagulating glands as whole, ovaries, uterus with cervix as applicable). Apart from the reproductive organs from all animals, from five adult males and females randomly selected from each group, the wet weight of the liver, kidneys, adrenals, thymus, spleen, brain and heart were taken as soon as possible.
- Paired organs were weighed separately and no organ weights would be taken for animals found dead.
- The following tissues of same selected animals were preserved in 10% formalin and their intended subsequent histopathological examinations: all gross lesions, brain, spinal cord, liver, kidneys, adrenals, stomach, small and large intestines (including Peyer´s patches), thymus, thyroid, spleen, trachea and lungs, heart, urinary bladder, lymph nodes, peripheral nerve and section of bone marrow.
HISTOPATHOLOGY: Yes
- Full histopathology was carried out on the preserved organs and tissues of the randomly selected animals (Male and Female) in the control and high dose groups.
- Testes, epididymides, ovaries, uterus with cervix, vagina, accessory sex organs (prostate, seminal vesicle with coagulating gland) and all organs showing gross lesions were examined in all animals.
- For testis, a detailed qualitative examination was made; taking into account the tubular stages of the spermatogenic cycle at evaluation of additional hematoxylin-PAS (Periodic Acid Schiff) stained slides.
- In decedents, lung, trachea, stomach (nonglandular and glandular), oesophagus, heart, adrenal gland and kidneys were evaluated. Macroscopic lesions, with the exception of observations made at mouth and nose, were evaluated in all study animals. - Other examinations:
- No
- Statistics:
- Parameters like body weight gain and food consumption were calculated for each animal as the difference in weight measured from one week to the next. The relative organ weights were calculated in relation to the body weight (measured at necropsy) and presented as percentage.
Dead animals were taken into the account in the analysis of parameters like body weight, food consumption, clinical signs and few reproductive parameters.
For statistical analysis, one-way analysis of variance (ANOVA) followed by Dunnett’s multiple comparison test was carried out to reveal any differences between control and test groups. These statistics were performed with GraphPad Prism V.5 software (p<0.05 was considered as statistical significant).
In the evaluation of laboratory parameters, all values within a range of the mean value +/- the two fold standard deviation (x +/- 2s) were considered to be "normal“ values within a "normal“ population.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- There were premature mortalities recorded in MD and HD groups. In view of the clinical and macroscopic findings recorded, gavage error or regurgitation cannot be excluded as cause of death for these rats
- Mortality:
- no mortality observed
- Description (incidence):
- There were premature mortalities recorded in MD and HD groups. In view of the clinical and macroscopic findings recorded, gavage error or regurgitation cannot be excluded as cause of death for these rats
- Body weight and weight changes:
- not examined
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- not examined
- Histopathological findings: neoplastic:
- not examined
- Details on results:
- Day of sacrifice
With the exception of some animals in MD and HD groups, all animals survived till the end of the study. Male animals were sacrificed on day 29 and 30. Non pregnant females were sacrificed on the respective day 26 after the sperm positive vaginal smear as an evidence of mating. Lactating females along with pups were sacrificed on respective post natal day 4.
Clinicals signs and mortality
No significant clinical findings were observed in the control and treatment groups of males and females, except for few incidental findings. They are not assumed to be related to systemic toxicity, but rather appear to be the sign of an acute local irritation caused by the test item.
Body weight
A statistically significant reduction in body weight development was observed in male HD group animals during the first week of pre mating period and the entire study duration. But for female animals, no such findings were reported in any of the treatment group as compared to the corresponding control group values. The statistically significant deviation observed in male HD group could be due to few low values in individual animals and may not be attributed to treatment. This finding was not correlated with the findings of food consumption.
Haematology
With some exception, no statistical significant deviations were recorded in any of the hematological parameters:
- The deviations from the biological range in the above parameters were slight and may not be attributed to treatment, but could be incidental.
- The statistically significant deviation observed for MCHC (Female MD) may not be attributed to toxicity due to lack of dose response effect.
- The statistically significant deviation observed in male HD group for the WBC mean value could be due to low values in two individual animals. No such deviation was statistically recorded for female animals. In keeping with the sensitivity of the female animals compared with males, this finding may not be directly attributed to treatment.
Clinical biochemistry
In most of the clinical biochemistry parameters evaluated, with exception, the data revealed no statistically significant deviation in both male and females. The exceptions are:
- The statistically significant deviation in GLU (female HD group) may not be attributed to treatment, but instead could be due to differential feeding of individual animals and were in the biological range.
- The deviation observed for ALBB value (male HD group) may not be toxicity related as macroscopically or microscopically no effect was observed in liver. This finding could be due to individual incidental values. The deviation observed for TP value (male HD group) is in correlation with the findings of ALBB value.Gross pathology
At terminal sacrifice, the only macroscopic organ lesions seen were yellowish foci in the epididymis of single males of all four study groups. Histologically, theese were confirmed to be spermatic granulomas and were considered to be incidental findings.
Ten animals were found dead during the study. These were two females and one male of MD group (female Nos. 21, 26 and male No. 62) and four females and three males of HD group (female Nos. 32, 33, 35, 38 and male Nos. 73, 75, 80). Macroscopic findings in these decedents were seen at mouth and nose (foam or food in 9/10 decedents), in the trachea (foam in 6/10 decedents, bloody infiltration in 1/10 decedents), in the stomach (foam or fluid in 4/10 decedents, rest of test item in 1/10 decedents) and in the lung (bloody in 8/10 decedents, foam or fluid content in 2/10 decedents).
Histopathology
All other histopathological changes seen in this study, in reproductive and other organs, were considered to be incidental in origin and/or within the range of expected changes for rats of this age and strain kept under laboratory conditions.
Effect levels
- Dose descriptor:
- NOAEL
- Effect level:
- >= 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- Under the condition of this study, for a period of 28-29 days for male and of 54 days (maximum) for female, the NOAEL of MgCl2, 6H2O by oral gavage to rat was 1000 mg/kg/day. No adverse effects were seen on general toxicity endpoints.
- Executive summary:
In conclusion, the repeated dose administration of Magnesium chloride hexahydrate in deionised water to the male (28-29 days) and female (maximum 54 days) Wistar rats at dosages of 250, 500 and 1000 mg/kg body weight revealed no major toxicological findings. The cause of death of animals during the conduct of the study could not be determined (a plausible cause may be gavaging error or regurgitation).
Based on the data generated from this combined repeated dose toxicity and reproduction/ developmental toxicity screening test with Magnesium chloride hexahydrate, the no observed adverse effect level (NOAEL) is believed to be 1000 mg/kg body weight for Magnesium chloride hexahydrate in males and females in Wistar rats.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.